Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognostication

Christina J. Perry(Macquarie University), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Philip Kaye(Nottingham University Hospitals NHS Trust), Krish Ragunath(Nottingham University Hospitals NHS Trust), Irshad Soomro, Elvin Hardy(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Dileep N. Lobo(Nottingham University Hospitals NHS Trust), Simon L. Parsons(Galapagos (Belgium)), Stewart G. Martin(University of Nottingham)
Diseases of the Esophagus
February 24, 2014
10.1111/dote.12190
Cited by 28

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations
|World Journal of Surgery|2016|607
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
|Gastroenterology|2012|378